Fedha

Hisa unazofuatilia
T1EV34:BVMF
Teva Pharmaceutical Industries Bdr
R$ 98.10
0.00%
(0.00) Siku 1
7 Okt, 13:35:03 GMT -3  ·   BRL
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya T1EV34...
Mtaji wa soko
47.12B
Wastani wa kiasi cha mauzo
127.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
R$ 101.90
Chini kwa wiki 52
R$ 51.60
Hisa za wawekezaji
1.17B
Idadi ya wafanyakazi
elfu 32
Mtaji wa soko
47.12B
Wastani wa kiasi cha mauzo
127.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
R$ 101.90
Chini kwa wiki 52
R$ 51.60
Hisa za wawekezaji
1.17B
Idadi ya wafanyakazi
elfu 32
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
Kuhusu Teva Pharmaceutical Industries Bdr
Afisa Mkuu Mtendaji (CEO)Richard Francis
Wafanyakazielfu 32
Lilianzishwa13 Feb 1944
Makao makuu-
Sekta-
Ripoti ya mwisho
29 Jul 2026
Kipindi cha Kifedha
Robo2 2026
US$ 0.02 / US$ 0.11
-81.46%hujafikia
Mapato dhidi ya makadirio (USD)
4.14B / 4.03B
+2.79%umepitiliza
Mkutano pepe wa kujadili mapato ya robo ya Robo ya 2 ya mwaka wa fedha wa 2026
Inasubiri mkutano pepe wa kujadili mapato
Kwa muhtasari
Maarifa kutoka kwenye ripoti na habari za hivi punde
Ripoti za awaliThamani zote katika USD
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika USD
Sep 2025
Des 2025
Mac 2026
Jun 2026
Mapato
4.48B
4.71B
3.98B
4.14B
Gharama ya bidhaa zilizouzwa
2.18B
2.06B
2.01B
1.99B
Gharama ya mapato
2.18B
2.06B
2.01B
1.99B
Gharama za utafiti na maendeleo
256.00M
267.00M
222.00M
970.00M
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
973.00M
1.12B
1.00B
1.03B
Gharama ya uendeshaji
1.24B
1.37B
1.21B
1.99B
Jumla ya gharama za uendeshaji
3.41B
3.43B
3.22B
3.98B
Mapato ya uendeshaji
1.07B
1.28B
763.00M
167.00M
Mapato mengine yasiyo ya uendeshaji
-27.00M
-
-13.00M
-69.00M
EBT ikijumuisha vipengee visivyo vya kawaida
648.00M
90.00M
436.00M
-455.00M
EBT bila kujumuisha vipengee visivyo vya kawaida
832.00M
1.08B
547.00M
-57.00M
Gharama ya kodi ya mapato
214.00M
-390.00M
67.00M
121.00M
Kiwango cha kodi kinachotumika
33.02%
-433.33%
15.37%
-26.59%
Gharama nyingine za uendeshaji
9.00M
-17.00M
-14.00M
-18.00M
Mapato halisi
433.00M
480.00M
369.00M
-576.00M
Kiwango cha faida halisi
9.67%
10.19%
9.27%
-13.91%
Mapato kwa kila hisa
0.78
0.96
0.53
0.02
Mapato ya riba na uwekezaji
-
92.00M
-
-
Gharama ya riba
-205.00M
-280.00M
-191.00M
-186.00M
Jumla ya gharama halisi za riba
-205.00M
-188.00M
-191.00M
-186.00M
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
1.32B
1.54B
1.00B
408.00M
Faida au hasara kutokana na uuzaji wa vipengee
-
-
-8.00M
-12.00M
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
Programu za Google